Transcript
A (0:02)
Amazon stock pops on a deal with Open Air, but can it fix its lagging grocery business? Our Monday merger moment to GLP1 Giants at War. We break down Pfizer's Fury and Novo Nordisk cunning in their battle to buy Sarah and Kimberly Clark buys Tylenol maker Ken View. Who stands to win and what is there to lose? For Monday, November 3rd, it's Blue Markets Daily and I'm Ann Barry.
B (0:29)
Three.
A (0:35)
More market details to come. But first, the big just keep getting bigger in the world of consumer staples. In food, Ferrero buys W.K. kellogg, Mars buys Kello Nova. In drink, Keurig Dr. Pepper buys J.D. pete. And now in consumer health with Kimberly Clark, maker of Huggies and Kleenex, buying kenbuild. That's the owner of Tylenol and Band Aid and which spun out of Johnson and Johnson only two and a half years ago. Ken View share price, though, has since dropped 35%. Now the almost $49 billion acquisition is a textbook play for scale by Kimberly Clark. With about $20 billion of its own annual revenue, Kimberly Clark is buying another consumer Staples asset about 75% of its own size, meaning a step change in its expanded ability to negotiate distribution terms with retailers, plus around $2 billion in net cost savings. Nevertheless, its shareholders are not happy. Kimberly Clark's stock dropped 14% in response to the news as investors struggle to figure out why the company would choose now, when its own stock is down year to date, to buy into Kenview's questionable growth prospects. Ken View sales, just to put it in context, were down 4% last quarter. Then there's the hot button issue of Tylenol. The brand is in the crosshairs of the Trump administration. On September 22, the White House posted a link to and the headline of a John Hopkins study stating that, quote, taking Tylenol during pregnancy, associated with elevated risks for autism, adhd. Not long after that, Ken View and its old parent J and J were sued by the state of Texas, claiming that the companies knew or should have known about possible neurological concerns associated with Tylenol, but didn't tell consumers. Now this is a lot for Kimberly Clark to be taking on. In contrast, Ken View shareholders saw their Stock soar nearly 15% today. They will get a mix of cash and Kimberly Clark shares in this deal, which is starting to look a lot like an extremely welcome escape hatch. We're going to keep on watching. There's a lot going on in this and a lot of political overtones going on here, too. Now coming up, Amazon stock hits an all time high, we break down why and GLP1 giants go to war this time in the world of acquisitions, we highlight the unusual battle happening right now between Pfizer and Novo Nordisk. But first, Brew Markets Daily is sponsored by Public, the platform for folks ready to take investing seriously. Public combines a wide range of asset classes with the tools you need to build and manage your wealth, whether it's with stocks, options, bonds and crypto. Our producer John recently signed up for Public.
